116 related articles for article (PubMed ID: 7259435)
1. The behaviour of tumour cells of ovarian carcinomata under in vitro conditions and the coincidence with clinical controllability of tumours.
Krafft W; Brückmann D; Brückmann J; Preibsch W; Behling H; Kademann J
Arch Geschwulstforsch; 1981; 51(1):133-8. PubMed ID: 7259435
[TBL] [Abstract][Full Text] [Related]
2. [Scintillation counting as an in vitro method for assessing the pretherapeutic effectiveness of planned tumor chemotherapy in patients with ovarian cancer].
Behling H; Krafft W; Wagner F
Zentralbl Gynakol; 1987; 109(1):42-8. PubMed ID: 3577462
[TBL] [Abstract][Full Text] [Related]
3. [Autoradiographic determination of 3H-thymidine incorporation in ovarian tumor cells and the value of this in vitro study for tumor chemotherapy].
Behling H; Krafft W; Wagner F
Zentralbl Gynakol; 1986; 108(11):684-90. PubMed ID: 3751378
[TBL] [Abstract][Full Text] [Related]
4. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
5. [Testing of sensitivity of human tumours to cytostatics in a rapid in vitro test (author's transl)].
Volm M
Dtsch Med Wochenschr; 1980 Oct; 105(43):1493-6. PubMed ID: 7428654
[TBL] [Abstract][Full Text] [Related]
6. Use of tritiated nucleotide incorporation for prediction of sensitivity of tumors to cytostatic agents.
Volm M
Behring Inst Mitt; 1984 May; (74):273-84. PubMed ID: 6383325
[TBL] [Abstract][Full Text] [Related]
7. [Registration of cytostatic effects on cultured cells in vitro and their current significance for individualized chemotherapy of tumors in advanced ovarian carcinoma].
Ebeling K; Spitzbart H
Zentralbl Gynakol; 1977; 99(17):1041-54. PubMed ID: 579017
[TBL] [Abstract][Full Text] [Related]
8. [Measurement of transmembrane potentials - a new method of in vitro tumor sensitivity testing].
Walliser S; Zipprich KW
Zentralbl Gynakol; 1984; 106(3):184-90. PubMed ID: 6702348
[TBL] [Abstract][Full Text] [Related]
9. [In-vitro testing of the sensitivity of mammary carcinoma cells to cytostatic drugs (author's transl)].
Bastert G; Schmidt-Matthiesen H; Gerner R; Michel RT; Nord D; Leppien G
Dtsch Med Wochenschr; 1975 Oct; 100(40):2035-42. PubMed ID: 1157720
[TBL] [Abstract][Full Text] [Related]
10. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
11. Cell cultures and their use in drug sensitivity prediction.
Dendy PP; Mitchell JS; Dawson A; Williamson J
Arch Geschwulstforsch; 1981; 51(1):111-8. PubMed ID: 7259433
[TBL] [Abstract][Full Text] [Related]
12. [Testing of solid tumors in childhood for sensitivity against cytostatic agents using an autoradiographic in vitro method (short-term method) (author's transl)].
Willnow U
Arch Geschwulstforsch; 1979; 49(3):201-10. PubMed ID: 227341
[TBL] [Abstract][Full Text] [Related]
13. [Studies into dependence of sensitivity of cytostatics on overlap index of ovarian cancer in cell cultures (author's transl)].
Schindler C
Zentralbl Gynakol; 1982; 104(3):156-9. PubMed ID: 7043954
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
15. [Attempt in determination of the sensitivity of ovarian neoplasms with ascites to cytostatics in tissue cultures].
Králová A
Cesk Gynekol; 1971 Sep; 36(7):437-8. PubMed ID: 5110668
[No Abstract] [Full Text] [Related]
16. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
Ness RB; Wisniewski SR; Eng H; Christopherson W
Anticancer Res; 2002; 22(2B):1145-9. PubMed ID: 12168915
[TBL] [Abstract][Full Text] [Related]
17. [Investigations for using cell- and organ culture in sensibility tests for cytostatics in human ovarial-carcinomas (author's transl)].
Hecker D; Saul G; Wolf G
Arch Geschwulstforsch; 1976; 46(1):34-43. PubMed ID: 962500
[TBL] [Abstract][Full Text] [Related]
18. [Perspectives of medical therapy of solid tumours].
Koza I
Vnitr Lek; 2001 Aug; 47(8):510-5. PubMed ID: 15633386
[TBL] [Abstract][Full Text] [Related]
19. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
Hall J; Paul J; Brown R
Expert Rev Mol Med; 2004 May; 6(12):1-20. PubMed ID: 15147608
[TBL] [Abstract][Full Text] [Related]
20. [Malignant ovarian germ cell tumours: a trial of 36 cases].
Gueye A; Narducci F; Baranzelli MC; Collinet P; Farine O; Fournier C; Vinatier D; Leblanc E
Gynecol Obstet Fertil; 2007 May; 35(5):406-19. PubMed ID: 17350873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
